Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis

References

• Cooper C. The epidemiology of osteoporosis. Osteoporos Int 1999;9(Suppl. 2):S2-8
   PubMed Web of Science ®Google Scholar
• NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95
   PubMed Web of Science ®Google Scholar
• Melton LJ III. How many women have osteoporosis now? J Bone Miner Res 1995;10:175-7
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-33
   PubMed Web of Science ®Google Scholar
• EPOS study group. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002;17:716-24
   PubMed Web of Science ®Google Scholar
• O’Neill TW, Felsenberg D, Varlow J, et al. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996;11:1010-18
   PubMed Web of Science ®Google Scholar
• Cooper C, O’Neill T, Silman A. The epidemiology of vertebral fractures. European Vertebral Osteoporosis Study Group. Bone 1993;14(Suppl. 1):S89-97
   Google Scholar
• Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7
   PubMed Web of Science ®Google Scholar
• Cauley JA, Palermo L, Vogt M, et al. Prevalent vertebral fractures in black women and white women. J Bone Miner Res 2008;23:1458-67
   PubMed Web of Science ®Google Scholar
• Cooper C, Atkinson EJ, O’Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989. J Bone Miner Res 1992;7:221-7
   PubMed Web of Science ®Google Scholar
• Fink HA, Milavetz DL, Palermo L, et al. What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res 2005;20:1216-22
   PubMed Web of Science ®Google Scholar
• Melton LJ III, Atkinson EJ, Cooper C, et al. Vertebral fractures predict subsequent fractures. Osteoporos Int 1999;10:214-21
   PubMed Web of Science ®Google Scholar
• Black DM, Arden NK, Palermo L, et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Miner Res 1999;14:821-8
   PubMed Web of Science ®Google Scholar
• Ross PD, Davis JW, Epstein RS, et al. Preexisting fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919-23
   PubMed Web of Science ®Google Scholar
• Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-39
   PubMed Web of Science ®Google Scholar
• Cauley JA, Hochberg MC, Lui LY, et al. Long-term risk of incident vertebral fractures. JAMA 2007;298:2761-7
   PubMed Web of Science ®Google Scholar
• Hodsman AB, Leslie WD, Tsang JF, et al. 10-year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort. An analysis from the Manitoba Bone Density Program. Arch Intern Med 2008;168:2261-7
   PubMed Web of Science ®Google Scholar
• Salaffi F, Cimmino MA, Malavolta N, et al. The burden of prevalent fractures on health-related qualify of life in postmenopausal women with osteoporosis: the IMOF study. J Rheumatol 2007;34:1551-60
   PubMed Web of Science ®Google Scholar
• Carliri A, De Filipis L, Bagnato GL, et al. Osteoporotic fractures: mortality and quality of life. Panminerva Med 2007;49:21-7
   PubMed Web of Science ®Google Scholar
• Brenneman SK, Barrett-Connor E, Sajjan S, et al. Impact of recent fracture on health-related quality of life in postmenopausal women. J Bone Miner Res 2006;21:809-16
   PubMed Web of Science ®Google Scholar
• Oleksik AM, Ewing S, Shen W, et al. Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures. Osteoporos Int 2005;16:861-70
   PubMed Web of Science ®Google Scholar
• Fechtenbaum J, Cropet C, Kolta S, et al. The severity of vertebral fractures and health-related quality of life in osteoporotic postmenopausal women. Osteoporos Int 2005;16:2175-79
   PubMed Web of Science ®Google Scholar
• Bianchi ML, Orsini MR, Saraifoger S, et al. Quality of life in post-menopausal osteoporosis. Health Qual Life Outcomes 2005;3:78
   PubMedGoogle Scholar
• Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998;128:793-800
   PubMed Web of Science ®Google Scholar
• Hall SE, Criddle RA, Comito TL, et al. A case–control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fractures. Osteoporos Int 1999;9:508-15
   PubMed Web of Science ®Google Scholar
• Huang C, Ross PD, Wasnich RD. Vertebral fracture and other predictors of physical impairment and health care utilization. Arch Intern Med 1996;156:2469-75
   PubMed Web of Science ®Google Scholar
• Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006;38(2 Suppl. 1):S4–S9
   PubMed Web of Science ®Google Scholar
• Kanis JA, Burlet N, Cooper C, et al. On behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Osteoporos Int 2008;19:399-428
   PubMed Web of Science ®Google Scholar
• Chesnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999;282:1344-52
   PubMed Web of Science ®Google Scholar
• Reginster JY, Minne HW, Sorenson OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures; results from the Fracture Intervention Trial. JAMA 1998;280:2077-82
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-45
   PubMed Web of Science ®Google Scholar
• Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Ortolani S, et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 2009;20:1663-73
   PubMed Web of Science ®Google Scholar
• Roux C, Fechtenbaum J, Kolta S, et al. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis 2008;67:1736-8
   PubMed Web of Science ®Google Scholar
• Reginster JY, Seeman E, De Vernejoul C, et al. Strontium ranelate reduces the risk of onvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22
   PubMed Web of Science ®Google Scholar
• Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis. Arthritis Rheum 2008;58:1687-95
   PubMed Web of Science ®Google Scholar
• Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-43
   PubMed Web of Science ®Google Scholar
• Seeman E, Boonen S, Borgström F, et al. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Bone 2010;46:1038-42
   PubMed Web of Science ®Google Scholar
• Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462-8
   PubMed Web of Science ®Google Scholar
• Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514-24
   PubMed Web of Science ®Google Scholar
• Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003;32:120-6
   PubMed Web of Science ®Google Scholar
• Black D, Schwartz A, Ensrud K, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX), a randomized trial. JAMA 2006;296:2927-38
   PubMed Web of Science ®Google Scholar
• Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial Long-Term Extension Research Group. J Bone Miner Res 2004;19:1259-69
   PubMed Web of Science ®Google Scholar
• Russell RGG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733–59
   PubMed Web of Science ®Google Scholar